Paper Review Records
All Paper Review Records
6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Tiffany R. King-Peoples; John T. Keane; Hyeon-Gyu S. Lewis; Fang Liu; Shawna K. Brookens; Oula K. Dagher; Kalpana Parvathaneni; Brittany L. Gardner; Amal Ahmed; Emma E. Furth; Priti Lal; Avery D. PoseyShow moreShow less
1. University of Pennsylvania 1 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 2. University of Pennsylvania 2 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, , Philadelphia, Pennsylvania.; 3. 3Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.Show moreShow less
In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models
Trishna Debnath; Won Jong Jin; Ravi B. Patel; Peter M. Carlson; Md Mahfuzur Rahman; Tracy J. Berg; Caroline P. Kerr; Rene Welch Schwartz; Yujuan Wang; Meredith Hyun; Irene M. Ong; Jamey P. Weichert; Reinier Hernandez; Paul M. Sondel; Zachary S. MorrisShow moreShow less
1. 1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 2. 2Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.; 3. Emory University 3 Department of Pediatrics, , Atlanta, Georgia.; 4. 4Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 5. 5Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 6. 6Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; 7. 7Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.Show moreShow less
VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer
Chuying Huo; Xibo Zhao; Dongdong Ye; Shaodan Lin; Dongdong Xu; Suen Wai Pang; Miaochun Xu; Junting Chen; Chunxian Huang; Yunyun Liu; Aoshuang Cheng; Lingjie Yang; Zhongqiu Lin; Lijuan Wang; Bowen Li; Huaiwu LuShow moreShow less
1. Sun Yat-sen Memorial Hospital 1 Department of Gynecologic Oncology, , Sun Yat-sen University, Guangzhou, China.; 2. Sun Yat-sen Memorial Hospital 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, , Sun Yat-sen University, Guangzhou, China.; 3. Sun Yat-sen Memorial Hospital 3 Department of Radiology, , Sun Yat-sen University, Guangzhou, China.; 4. Sun Yat-sen Memorial Hospital 4 Department of Oral and Maxillofacial Surgery, , Sun Yat-sen University, Guangzhou, China.Show moreShow less
Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity
Daisuke Ehara; Kiyoshi Yasui; Mitsuhiro Yoneda; Daisuke Muraoka; Situo Deng; Pengyu Miao; Chenxu Jiang; Huimin Sun; Sachiko Okamoto; Yasunori Amaishi; Hiroyuki Murota; Hiroaki IkedaShow moreShow less
1. 1Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; 2. 2Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; 3. 3Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.; 4. 4Takara Bio Inc., Kusatsu, Japan.; 5. 5Leading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.Show moreShow less
Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity
Daniel R. Lu; Tao Osgood; Shining Ma; Huajia Zhang; Matt Kanke; Jessica A. Tan; Siddhi N. Paudel; Hong Zhou; Juan Estrada; Tracy Yamawaki; Kristin Tarbell; Karen Rex; Jason DeVoss; Scott Martin; Songli Wang; Jude Canon; J. Russell Lipford; Angela Coxon; Chi-Ming LiShow moreShow less
1. 1Target Discovery & Biology of DATA, Amgen Global Research, South San Francisco, California.; 2. 2Oncology Research, Amgen Global Research, Thousand Oaks, California.; 3. 3ARIA of DATA, Amgen Global Research, South San Francisco, California.; 4. Amgen Global Research 4 Oncology Research, , South San Francisco, California.Show moreShow less
Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy
Christianne Groeneveldt; Disha Vadgama; Anne Onrust-van Schoonhoven; Declan Whyte; Maaike M. Hofman; Nina E.M. Rozendaal; Menno van Nimwegen; Mike Eterman; Daphne W. Dumoulin; Ron H.J. Mathijssen; Arjen Joosse; Astrid A.M. van der Veldt; Louis Boon; Michail Doukas; Janneke N. Samsom; Ralph Stadhouders; Floris Dammeijer; Joachim G.J.V. Aerts; Maria E. JoosseShow moreShow less
1. Department of Pulmonary Medicine, Erasmus University Medical Center , Rotterdam, the Netherlands.; 2. Erasmus MC Cancer Institute , Erasmus University Medical Center, Rotterdam, the Netherlands.; 3. Department of Medical Oncology, Erasmus University Medical Center , Rotterdam, the Netherlands.; 4. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center , Rotterdam, the Netherlands.; 5. JJP Biologics, Warsaw, Poland.; 6. Department of Pathology, Erasmus University Medical Center , Rotterdam, the Netherlands.; 7. Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center-Sophia Children’s Hospital, Rotterdam, the Netherlands.Show moreShow less
FAQ
How long does Cancer Immunology Research take to review a manuscript?
As of 2026-11-19, CrushSCI has 6 complete review records for Cancer Immunology Research. The fastest paper went from submission to acceptance in 180 days (CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance, received 2026-01-02, accepted 2026-07-01); the slowest took 364 days. The average is 262.7 days and the median is 262 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
